uniQure N.V. Logo

uniQure N.V.

QURE

(1.2)
Stock Price

9,11 USD

-28.98% ROA

-99.31% ROE

-1.34x PER

Market Cap.

306.949.830,00 USD

51.45% DER

0% Yield

-1947.09% NPM

uniQure N.V. Stock Analysis

uniQure N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

uniQure N.V. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.93x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (39%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-44.91%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-21.79%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

uniQure N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

uniQure N.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

uniQure N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

uniQure N.V. Revenue
Year Revenue Growth
2011 0
2012 0 0%
2013 4.063.907 100%
2014 5.697.018 28.67%
2015 10.304.375 44.71%
2016 25.098.000 58.94%
2017 13.107.000 -91.49%
2018 11.284.000 -16.16%
2019 7.281.000 -54.98%
2020 37.514.000 80.59%
2021 524.002.000 92.84%
2022 106.483.000 -392.1%
2023 5.628.000 -1792.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

uniQure N.V. Research and Development Expenses
Year Research and Development Expenses Growth
2011 20.089.430
2012 13.530.563 -48.47%
2013 18.202.657 25.67%
2014 41.261.735 55.88%
2015 51.145.781 19.33%
2016 72.510.000 29.46%
2017 72.383.000 -0.18%
2018 74.809.000 3.24%
2019 94.737.000 21.04%
2020 122.400.000 22.6%
2021 143.548.000 14.73%
2022 197.591.000 27.35%
2023 261.600.000 24.47%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

uniQure N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 0
2012 6.035.919 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

uniQure N.V. EBITDA
Year EBITDA Growth
2011 -21.416.629
2012 -18.013.860 -18.89%
2013 -30.977.105 41.85%
2014 -39.068.048 20.71%
2015 -56.639.626 31.02%
2016 -71.946.000 21.27%
2017 -63.773.000 -12.82%
2018 -73.088.000 12.74%
2019 -110.924.000 34.11%
2020 -113.840.000 2.56%
2021 317.919.000 135.81%
2022 -134.013.000 337.23%
2023 -327.508.000 59.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

uniQure N.V. Gross Profit
Year Gross Profit Growth
2011 0
2012 0 0%
2013 2.959.209 100%
2014 5.697.018 48.06%
2015 9.665.887 41.06%
2016 25.098.000 61.49%
2017 13.107.000 -91.49%
2018 11.284.000 -16.16%
2019 7.281.000 -54.98%
2020 37.514.000 80.59%
2021 499.026.000 92.48%
2022 103.140.000 -383.83%
2023 1.604.000 -6330.17%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

uniQure N.V. Net Profit
Year Net Profit Growth
2011 -22.422.396
2012 -19.462.004 -15.21%
2013 -37.034.991 47.45%
2014 -45.041.101 17.78%
2015 -78.149.258 42.37%
2016 -73.374.000 -6.51%
2017 -80.389.000 8.73%
2018 -83.304.000 3.5%
2019 -128.011.000 34.92%
2020 -125.024.000 -2.39%
2021 329.589.000 137.93%
2022 -126.789.000 359.95%
2023 -358.284.000 64.61%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

uniQure N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -1
2012 -1 0%
2013 -2 50%
2014 -3 0%
2015 -4 33.33%
2016 -3 -50%
2017 -3 0%
2018 -2 0%
2019 -3 33.33%
2020 -3 -50%
2021 7 128.57%
2022 -3 450%
2023 -8 71.43%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

uniQure N.V. Free Cashflow
Year Free Cashflow Growth
2011 -22.051.714
2012 -16.163.673 -36.43%
2013 -13.979.950 -15.62%
2014 -54.186.731 74.2%
2015 9.361.949 678.8%
2016 -89.361.000 110.48%
2017 -69.853.000 -27.93%
2018 -80.282.000 12.99%
2019 -105.331.000 23.78%
2020 -144.312.000 27.01%
2021 270.521.000 153.35%
2022 -162.748.000 266.22%
2023 37.211.000 537.37%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

uniQure N.V. Operating Cashflow
Year Operating Cashflow Growth
2011 -21.651.222
2012 -14.913.905 -45.17%
2013 -5.711.287 -161.13%
2014 -30.917.117 81.53%
2015 18.776.376 264.66%
2016 -72.189.000 126.01%
2017 -64.270.000 -12.32%
2018 -76.037.000 15.48%
2019 -98.684.000 22.95%
2020 -134.828.000 26.81%
2021 287.959.000 146.82%
2022 -145.060.000 298.51%
2023 38.911.000 472.8%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

uniQure N.V. Capital Expenditure
Year Capital Expenditure Growth
2011 400.493
2012 1.249.769 67.95%
2013 8.268.662 84.89%
2014 23.269.614 64.47%
2015 9.414.427 -147.17%
2016 17.172.000 45.18%
2017 5.583.000 -207.58%
2018 4.245.000 -31.52%
2019 6.647.000 36.14%
2020 9.484.000 29.91%
2021 17.438.000 45.61%
2022 17.688.000 1.41%
2023 1.700.000 -940.47%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

uniQure N.V. Equity
Year Equity Growth
2010 18.165.980
2011 -3.360.767 640.53%
2012 -592.483 -467.24%
2013 7.683.173 107.71%
2014 52.390.680 85.33%
2015 130.632.147 59.89%
2016 63.631.000 -105.3%
2017 89.945.000 29.26%
2018 179.606.000 49.92%
2019 323.058.000 44.4%
2020 243.905.000 -32.45%
2021 595.776.000 59.06%
2022 476.009.000 -25.16%
2023 268.784.000 -77.1%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

uniQure N.V. Assets
Year Assets Growth
2010 30.194.175
2011 7.522.520 -301.38%
2012 7.362.393 -2.17%
2013 53.811.207 86.32%
2014 116.476.969 53.8%
2015 264.690.705 56%
2016 190.265.000 -39.12%
2017 208.877.000 8.91%
2018 273.906.000 23.74%
2019 448.630.000 38.95%
2020 340.395.000 -31.8%
2021 809.180.000 57.93%
2022 704.964.000 -14.78%
2023 871.550.000 19.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

uniQure N.V. Liabilities
Year Liabilities Growth
2010 12.028.195
2011 10.883.287 -10.52%
2012 7.954.876 -36.81%
2013 46.128.034 82.75%
2014 64.086.288 28.02%
2015 134.058.557 52.2%
2016 126.634.000 -5.86%
2017 118.932.000 -6.48%
2018 94.300.000 -26.12%
2019 125.572.000 24.9%
2020 96.490.000 -30.14%
2021 213.404.000 54.79%
2022 228.955.000 6.79%
2023 602.766.000 62.02%

uniQure N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.34
Net Income per Share
-4.78
Price to Earning Ratio
-1.34x
Price To Sales Ratio
2.74x
POCF Ratio
-2.03
PFCF Ratio
-1.9
Price to Book Ratio
1.14
EV to Sales
1.93
EV Over EBITDA
-1.18
EV to Operating CashFlow
-1.43
EV to FreeCashFlow
-1.34
Earnings Yield
-0.74
FreeCashFlow Yield
-0.53
Market Cap
0,31 Bil.
Enterprise Value
0,22 Bil.
Graham Number
24.61
Graham NetNet
1.36

Income Statement Metrics

Net Income per Share
-4.78
Income Quality
0.66
ROE
-0.6
Return On Assets
-0.37
Return On Capital Employed
-0.37
Net Income per EBT
1.01
EBT Per Ebit
1.08
Ebit per Revenue
-17.85
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
2.06
Stock Based Compensation to Revenue
0.36
Gross Profit Margin
0.14
Operating Profit Margin
-17.85
Pretax Profit Margin
-19.35
Net Profit Margin
-19.47

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.16
Free CashFlow per Share
-3.38
Capex to Operating CashFlow
0.07
Capex to Revenue
-0.09
Capex to Depreciation
-1.01
Return on Invested Capital
-0.44
Return on Tangible Assets
-0.29
Days Sales Outstanding
5.36
Days Payables Outstanding
316.34
Days of Inventory on Hand
886.81
Receivables Turnover
68.07
Payables Turnover
1.15
Inventory Turnover
0.41
Capex per Share
-0.21

Balance Sheet

Cash per Share
13,79
Book Value per Share
5,63
Tangible Book Value per Share
3.88
Shareholders Equity per Share
5.63
Interest Debt per Share
2.86
Debt to Equity
0.51
Debt to Assets
0.16
Net Debt to EBITDA
0.5
Current Ratio
10.11
Tangible Asset Value
0,19 Bil.
Net Current Asset Value
0,09 Bil.
Invested Capital
0.51
Working Capital
0,63 Bil.
Intangibles to Total Assets
0.1
Average Receivables
0,05 Bil.
Average Payables
0,01 Bil.
Average Inventory
12933000
Debt to Market Cap
0.45

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

uniQure N.V. Dividends
Year Dividends Growth

uniQure N.V. Profile

About uniQure N.V.

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

CEO
Mr. Matthew Craig Kapusta
Employee
480
Address
Paasheuvelweg 25a
Amsterdam, 1105 BP

uniQure N.V. Executives & BODs

uniQure N.V. Executives & BODs
# Name Age
1 Ms. Carla Poulson
Interim Chief People and Culture Officer
70
2 Ms. Maria E. Cantor
Chief Corporate Affairs Officer
70
3 Mr. Richard Porter Ph.D.
Chief Business & Scientific Officer
70
4 Dr. Jeannette Potts J.D., Ph.D.
Chief Legal & Compliance Officer
70
5 Prof. Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
70
6 Dr. Amin Abujoub Ph.D.
Chief Quality Officer
70
7 Mr. Christian Klemt
Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
70
8 Dr. Tamara Tugal Ph.D., MBA
Business Development Director
70
9 Mr. Matthew Craig Kapusta
Chief Executive Officer & Executive Director
70
10 Mr. Pierre Caloz
Chief Operating Officer
70

uniQure N.V. Competitors